Leerink Swann began coverage on shares of Affimed (NASDAQ:AFMD) in a research note issued to investors on Thursday, March 28th, Benzinga reports. The firm issued an outperform rating and a $4.17 price objective on the biopharmaceutical company’s stock.
AFMD has been the subject of several other reports. Zacks Investment Research raised Affimed from a sell rating to a hold rating in a research note on Thursday, January 3rd. ValuEngine cut Affimed from a buy rating to a hold rating in a research note on Tuesday, January 29th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $5.15.
Shares of Affimed stock traded down $0.10 during midday trading on Thursday, hitting $3.35. 1,180,519 shares of the company were exchanged, compared to its average volume of 1,409,313. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.01 and a quick ratio of 3.00. Affimed has a 52 week low of $1.40 and a 52 week high of $7.35. The company has a market capitalization of $209.01 million, a PE ratio of -8.82 and a beta of 3.41.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. acquired a new stake in shares of Affimed during the fourth quarter worth $36,000. Lindbrook Capital LLC acquired a new stake in shares of Affimed during the fourth quarter worth $38,000. FDx Advisors Inc. acquired a new stake in shares of Affimed during the fourth quarter worth $87,000. CIBC World Markets Inc. acquired a new stake in shares of Affimed during the third quarter worth $104,000. Finally, Deutsche Bank AG grew its stake in shares of Affimed by 2,243.6% during the fourth quarter. Deutsche Bank AG now owns 49,074 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 46,980 shares during the period. 41.06% of the stock is owned by institutional investors.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: Short Selling
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.